Decoy Therapeutics shareholders approve 2026 equity plan and reverse stock split

Decoy Therapeutics Inc.

Approved 2026 Equity Incentive Plan: 351,837 for, 68,978 against, 55,703 abstentions.
Approved reverse stock split of common stock at ratio between 1:4 and 1:15, at board's discretion.
Reverse split proposal: 2,187,125 votes for, 507,474 against, 2,173 abstentions.
Adjournment proposal was unnecessary due to sufficient votes; broker non-votes totaled 2,220,254.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.